Dr. Silvia Cingelova | Authentic Leadership | Best Researcher Award
National Cancer Institute, Slovakia
Profile
Early Academic Pursuits 🎓
Dr. Silvia Cingelová’s journey into the world of medicine and oncology began with a solid academic foundation, characterized by her unwavering commitment to education and excellence. She embarked on her academic career at the Faculty of Medicine, Comenius University in Bratislava, Slovakia, where she earned her MUDr. (Doctor of Medicine) degree in 2004. This achievement marked the beginning of a promising career in the medical field.
Her thirst for knowledge and her desire to expand her expertise led her to pursue further education. She obtained a Master’s degree with the academic title Ing. from the Faculty of Economic Informatics at The University of Economics in Bratislava in 2007. This multidisciplinary approach provided her with a unique perspective, blending medical knowledge with economic and informatics skills, equipping her to address the complexities of healthcare management and patient care in innovative ways.
In addition to her medical degree, Dr. Cingelová also completed postgraduate studies at the Vienna School of Clinical Research in Austria between 2005 and 2007. Her education continued with the pursuit of a PhD at the Faculty of Health Sciences and Social Work at the University of Trnava, Slovakia, where she deepened her research skills and focused on health sciences, completing this in 2013. Her diverse academic background laid a strong foundation for her future endeavors in the field of oncohematology.
Professional Endeavors 💼
Dr. Cingelová’s professional journey is a testament to her dedication and expertise in the field of oncohematology. After earning her M.D., she began her career as a junior physician at the Oncology Clinics in Trnava, Slovakia, where she worked from 2004 to 2013. During this time, she honed her skills in diagnosing and treating various forms of cancer, gaining invaluable experience in the intricacies of oncology.
In 2013, she transitioned to the Národný onkologický ústav (National Cancer Institute) in Bratislava, Slovakia, where she took on the role of an Oncohematologist in the Department of Oncohematology II. Her work in this prestigious institution has allowed her to focus on the treatment and research of blood cancers, including leukemia, lymphoma, and myeloma. Dr. Cingelová’s dedication to patient care, coupled with her comprehensive knowledge of hematologic malignancies, has made her a key figure in the department, contributing to both clinical practice and ongoing research.
Contributions and Research Focus 🧬
Dr. Cingelová’s research interests are deeply rooted in the field of oncohematology, where she has made significant contributions to understanding the complexities of hematologic cancers. Her work is characterized by a commitment to improving patient outcomes through innovative treatment approaches and the integration of clinical research into everyday practice. Her PhD work, combined with her clinical experience, has positioned her as a thought leader in her field, with a focus on translational research that bridges the gap between laboratory discoveries and clinical application.
Her research is not limited to the lab; she actively participates in clinical trials, evaluating new therapies and treatment protocols that could potentially revolutionize the management of blood cancers. By contributing to groundbreaking studies, Dr. Cingelová is at the forefront of advancing the field of oncohematology, providing patients with access to the latest and most effective treatment options.
Accolades and Recognition 🏆
Throughout her career, Dr. Cingelová has received numerous accolades that recognize her contributions to medicine and research. Her achievements in both clinical practice and research have earned her a reputation as a leading expert in oncohematology. Colleagues and patients alike commend her for her dedication, compassion, and relentless pursuit of excellence.
Dr. Cingelová’s work has been acknowledged not only within Slovakia but also on an international level. Her participation in international conferences and collaborations has brought her recognition in the global medical community, further solidifying her standing as an expert in her field. These accolades are a testament to her impact and influence in the medical community, particularly in the realm of cancer treatment and research.
Impact and Influence 🌍
Dr. Cingelová’s impact extends far beyond her immediate work environment. As an oncohematologist, her influence is seen in the improved outcomes of countless patients who have benefited from her expertise. She is known for her patient-centered approach, which emphasizes compassionate care and individualized treatment plans. This approach has not only improved patient satisfaction but also contributed to better clinical outcomes.
Her influence is also evident in the mentorship she provides to younger physicians and medical students. Dr. Cingelová is committed to sharing her knowledge and experience with the next generation of healthcare professionals, ensuring that her legacy of excellence continues through those she has trained and inspired.
Legacy and Future Contributions 🌟
Looking ahead, Dr. Cingelová is poised to continue making significant contributions to the field of oncohematology. Her ongoing research and clinical work will undoubtedly lead to new insights and advancements in the treatment of blood cancers. As she continues to mentor the next generation of physicians and engage in cutting-edge research, her legacy will be one of innovation, compassion, and unwavering dedication to the fight against cancer.
In the years to come, Dr. Cingelová’s work will likely influence the direction of oncohematology, shaping the future of cancer care. Her legacy will be defined not only by her professional achievements but also by the lives she has touched through her compassionate care and commitment to advancing medical science.
Publications
Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer
Authors: Z Cierna, M Mego, P Janega, M Karaba, G Minarik, J Benca, et al.
Journal: BMC Cancer
Volume: 14
Issue: Not specified (article number)
Pages: 1-8
Year: 2014
CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer
Authors: M Mego, D Cholujova, G Minarik, T Sedlackova, P Gronesova, M Karaba, et al.
Journal: BMC Cancer
Year: 2016
Long-term cognitive functioning in testicular germ-cell tumor survivors
Authors: M Chovanec, L Vasilkova, L Setteyova, J Obertova, P Palacka, et al.
Journal: The Oncologist
Year: 2018
Plasma cytokines correlated with disease characteristics, progression-free survival, and overall survival in testicular germ-cell tumor patients
Authors: D Svetlovska, V Miskovska, D Cholujova, P Gronesova, S Cingelova, et al.
Journal: Clinical Genitourinary Cancer
Year: 2017
The prognostic value of DNA damage level in peripheral blood lymphocytes of chemotherapy-naïve patients with germ cell cancer
Authors: Z Sestakova, K Kalavska, L Hurbanova, D Jurkovicova, J Gursky, et al.
Journal: Oncotarget
Year: 2016
Plasma thiobarbituric acid reactive substances predicts survival in chemotherapy naïve patients with metastatic urothelial carcinoma
Authors: J Slopovsky, J Kucharska, J Obertova, M Mego, K Kalavska, S Cingelova, et al.
Journal: Translational Oncology
Year: 2021